Forward-Looking Statements and Kitov’s Safe Harbor Statement

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction. Certain statements in this presentation are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully acquire, develop or commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2017 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, http://www.sec.gov.
Company Profile

Innovative Biopharmaceutical Company
Leveraging Deep Regulatory and Drug Development Expertise

DIVERSE PIPELINE ADDRESSING LARGE MARKETS

- Lead drug candidate Consensi™ (formerly KIT-302) approved by FDA (May 2018) to treat osteoarthritic pain and hypertension
- NT219 - small molecule designed to overcome cancer drug resistance

PROVEN TEAM

- Consensi™ manufacturing and CMC work partnered with Dexcel Pharma, Israel’s largest private pharmaceutical company
- Management team with proven track record in drug development, NDA submissions and FDA approvals

COMPELLING VALUE

- Founded in 2010; publicly traded on TASE 2013; IPO on NASDAQ in November 2015
- Tickers: KTOV (ADSs); KTOVW (Warrants)
- Cash on hand (as of June 30, 2018): $11.8M; no debt
- Market Cap: $21M*
- Issued & outstanding capital equivalent to 16.0 million ADSs**

* As of November 12, 2018
** Each ADS = 20 ordinary shares
Experienced Management

Paul Waymack, M.D., Sc.D.
Chairman of the Board & Chief Medical Officer
Former FDA medical officer

Gil Efron
Deputy CEO and Chief Financial Officer
Formerly at Kamada (NASDAQ: KMDA)

Hadas Reuveni, Ph.D.
Founder & Chief Technology Officer - TyrNovo
Formerly at Keryx (NASDAQ: KERX)

Isaac Israel
Chief Executive Officer
Former CEO of BeeContact (TASE: BCNT), NextGen Biomed (TASE: NXGN)

Gil Ben-Menachem, Ph.D., MBA
Vice President, Business Development
Formerly at Paramount, Teva, Dexcel, NIH
## Pipeline

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Field</th>
<th>Preclinical</th>
<th>Phase I/II</th>
<th>Phase III</th>
<th>Submission</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consensi™</td>
<td>Osteoarthritis pain and hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NT219</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
About Consensi™

Full US Prescribing Information is available at: www.consensi.com

Fixed dose combination of Celecoxib, a COX-2 selective NSAID (the active ingredient in Pfizer’s Celebrex®)

+ Amlodipine, a blood pressure-lowering agent (a calcium channel blocker) (the active ingredient in Pfizer’s Norvasc®)

Simultaneous treatment of osteoarthritic pain and hypertension

Approved for marketing by U.S FDA on May 31, 2018

- Clinical data showed Consensi™ was more effective at lowering blood pressure than amlodipine alone
- Clinical data also demonstrated beneficial renal function measures
- Formulated with 200 mg celecoxib and three different dosages (2.5, 5, 10 mg) of amlodipine
- Manufactured by Dexcel Pharma – Israel largest private pharmaceutical company. Tech transfer for local manufacturing is possible

*Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.).
Norvasc® is a registered trademark of Pfizer Inc.
Medical Rationale

Celecoxib (the active ingredient in Pfizer's Celebrex®)

- The only widely prescribed selective COX-2 NSAID approved in the US (unlike non-selective NSAIDs, celecoxib carries limited gastrointestinal risks)
- Since 2005, has an FDA-mandated “black box” label warning of increased cardiovascular risks
- According to FDA, cardiovascular risks can occur as early as the first few weeks of using an NSAID, and may increase with longer use

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS
See full prescribing information for complete boxed warning

Cardiovascular Risk
- CELEBREX, may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs may have a similar risk. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (5.1.14.7)

Amlodipine (the active ingredient in Pfizer's Norvasc®)

- Calcium channel blocker; anti-hypertensive
- Unlike other blood pressure-lowering drug groups – such as diuretics, ACE inhibitors, and angiotensin II receptor antagonists – calcium channel blockers do not cause deterioration of renal function, including possible acute renal failure*

* The FDA Safety Information and Adverse Event Reporting Program; http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm270998.htm
Consensi™ Phase III Trial Design

Newly diagnosed hypertensive patients

Double-blind, placebo-controlled, multi-center study
- N = 152
- 4-arm trial with 30-45 patients in each arm
- 2 weeks of treatment

Data Collection and Statistical Analysis

Primary endpoint
Demonstrate that the reduction in blood pressure in the Consensi™ arm is at least 50% of the reduction in the amlodipine arm

Measurement of pain was not required by FDA
Consensi™ Phase III Trial Results

- Primary efficacy endpoint was successfully achieved (P=0.001)
- Demonstrated 2.5x better blood pressure reduction than FDA requirement (50% of amlodipine arm)
- Demonstrated consistent reduction in all measures of blood pressure
- Observed beneficial renal functions:
  - Creatinine plasma level reduction
    - Consensi™: -3.22 μmol/L
    - Amlodipine: -2.55 μmol/L
  - Peripheral edema (% patients)
    - Consensi™: 8.2%
    - Amlodipine: 15.6%

Consensi™ demonstrated even better BP reduction than same amount of amlodipine given without celecoxib

* Error bars – standard error of mean

Additional Phase III/IV clinical trial to scientifically validate the renal benefits (not required for NDA submission) was completed. Topline results were announced in October, 2017.
Consensi™ Phase III/IV Clinical Trial Design

Hypertensive patients (following a wash-out period)

Double-blind, placebo-controlled, multi-center study

- N = 102
- 3-arm trial
- 2 weeks of treatment

Data Collection and Statistical Analysis

Consensi™  Celecoxib 200 mg + Amlodipine 10 mg

AMLODIPINE 10 mg

PLACEBO

Primary endpoint

Demonstrate that the reduction in blood pressure in the Consensi™ arm is at least 50% of the reduction in the amlodipine arm

Secondary endpoints

Improvements of renal function measurements
Consensi™ Phase III/IV Clinical Trial Results

- Primary efficacy endpoint successfully met (p=0.019), thus Phase III trial results validated
- Statistically significant reduction of serum creatinine observed vs. baseline
- Consensi™ enhanced the creatinine reduction by an average of 102% vs. amlodipine alone
- Consensi™ demonstrated systolic blood-pressure reduction comparable to amlodipine

<table>
<thead>
<tr>
<th></th>
<th>Consensi™ (n=48)</th>
<th>Amlodipine (n=49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine plasma level reduction</td>
<td>-3.48 μmol/L</td>
<td>-1.72 μmol/L</td>
</tr>
<tr>
<td>p-value</td>
<td>0.0005</td>
<td>0.075</td>
</tr>
</tbody>
</table>
Consensi™ US Target Markets

Consensi™ targets osteoarthritic patients currently treated with NSAIDs (celecoxib as well as others) who also suffer from existing or newly diagnosed hypertension.

**Arthritis Prevalence**
- More than 50 million adults in the US have doctor-diagnosed osteoarthritis.
- 67 million people are expected to have doctor-diagnosed osteoarthritis by 2030.

**Hypertension Prevalence**
- 29% of US adults older than 18.
- 65% of US adults older than 60.

**Comorbidities**
- 44% of adults with high blood pressure have osteoarthritis.

Consensi™ Benefits All Stakeholders

Consensi™ is the only NSAID whose labeling indicate reduction of blood pressure and consequent risk reduction of heart attack, stroke and death.

- **Patients**
  - Treats two conditions simultaneously
  - Increases convenience (one pill instead of two)
  - Lowers co-pay

- **Physicians**
  - Improves patient compliance
  - Reduces concerns related to NSAID side effects

- **Payors**
  - Lowers disease burden
  - Improves patient health
  - Lowers overall healthcare costs
Consensi™ Commercialization

Ongoing partnership discussions in the US and other territories

China - Exclusively licensed to Changshan Pharma. Milestone payments up to $9.5M, double-digit royalties (May 2018)

South Korea - Exclusively licensed to Kuhnil Pharmaceuticals (March 2017)
## Pipeline

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic Field</th>
<th>Preclinical</th>
<th>Phase I/II</th>
<th>Phase III</th>
<th>Submission</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consensi™</td>
<td>Osteoarthritis pain and hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NT219</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NT219: Overcoming Cancer Drug Resistance

- A novel small molecule that prevents, reverses, and delays resistance to anti-cancer drugs
  - Dual inhibitor of STAT3 and IRS1/2: two signal pathways associated with drug resistance
  - Demonstrated outstanding efficacy in patient-derived xenograft (PDX) models
- Favorable response received from FDA in a pre-IND meeting
- Preclinical work ongoing; IND expected 2019
- Initial clinical trial expected in pancreatic cancer patients in combination with gemcitabine (Gemzar®) and/or in combination with osimertinib (Tagrisso™) for the treatment of non-small cell lung cancer (NSCLC)
- Long-term strategy to develop NT219, in combination with other oncology drugs for additional indications, on our own or in collaboration with strategic partners who have expressed solid preliminary interest in the drug
NT219: Mechanism of Action

- Anti-cancer drugs induce activation of two feedback pathways, STAT3 and IRS, which are involved in the development of tumor resistance
- NT219 blocks both STAT3 and IRS1/2, and enhances the tumors response to the approved drugs
- STAT3 is known to be active in the immune evasion mechanism of the tumor
Results in PDX Models

NT219 Prevents Acquired Resistance to EGFR Inhibitor (Tarceva®) in Head and Neck Cancer

![Graph showing tumor volume over days for different treatments including Vehicle, Erlotinib, NT219, Erlotinib+NT219, and Complete response. The graph indicates that NT219 prevents resistance to Erlotinib.]
Results in PDX Models (cont’d)

NT219 Reverses Existing Resistance to Tarceva® in Head and Neck Tumors

- **Erlotinib:**
  - Response
  - Acquired resistance

Treatment with NT-219+Erlotinib after resistance is acquired leads to regression of Erlotinib-resistant tumor
Results in PDX Models (cont’d)

NT219 Delays Recurrence of Tumors of Head and Neck with Cetuximab

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tumor Recurrence (days following end of treatment)</th>
<th>Average</th>
<th>Stdev</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n=4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NT219 (n=4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetuximab (n=4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetuximab+NT219</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Control (n=4)
- NT219 (n=4)
- Cetuximab (n=4)
- NT219+Cetuximab (n=4)
- Cetuximab+NT219 (n=1/4)
- Cetuximab+NT219 (n=3/4)

![Graph showing tumor volume over time with different treatments.](image)
Results in PDX Models (cont’d)

NT219 Prevents Acquired Resistance to MEK Inhibitor (Mekinist®) in Mutated-BRAF Anaplastic Thyroid Cancer
Results in Immuno-Oncology PDX Model in Combination with Keytruda®

NT219 Converts Non-Responding Tumors to Keytruda® to Responders in Humanized PDX of Esophagus Cancer

Double autologous model - tumors and PBMCs of the same patient
Efficacy in Pancreatic Cancer Models

NT219 Converts Non-Responding Tumors to Responders to Gemcitabine in 4/4 PDX Models of Pancreatic Cancer

![Graphs showing tumor volume changes over time for different treatment groups.]

- **Non-Responders**
  - Control (n=7)
  - NT219 (n=7)
  - Gemcitabine (n=15)
  - Gemcitabine+NT219 (n=8)

- **Responders**
  - Control (n=5)
  - NT219 (n=5)
  - Gemcitabine (n=5)
  - Gemcitabine+NT219 (n=5)
## Summary of Demonstrated Efficacy

NT219 will be developed in combination with approved oncology drugs to increase efficacy, expand target population, and extend treatment duration.

<table>
<thead>
<tr>
<th>TYPE</th>
<th>DRUG (TRADE NAME)</th>
<th>CANCER TYPE</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antibody</strong></td>
<td>Cetuximab (Erbitux®)</td>
<td>Head and Neck</td>
<td>Merck / Eli Lilly</td>
</tr>
<tr>
<td></td>
<td>Cetuximab (Erbitux®) +</td>
<td>Colon (wt KRAS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FOLFOX/FOLFIRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Kinase Inhibitors</strong></td>
<td>Erlotinib (Tarceva®)</td>
<td>Head and Neck</td>
<td>Roche / Astellas</td>
</tr>
<tr>
<td></td>
<td>Afatinib (Giotrif®)</td>
<td>Head and Neck</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td></td>
<td>Osimertinib (Tagrisso®)</td>
<td>Lung</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Vemurafenib (Zelboraf®)</td>
<td>Melanoma</td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Trametinib (Mekinist®)</td>
<td>Thyroid</td>
<td>Novartis</td>
</tr>
<tr>
<td></td>
<td>Everolimus (Afinitor®)</td>
<td>Uterine Adenosarcoma</td>
<td>Novartis</td>
</tr>
<tr>
<td><strong>Chemotherapy</strong></td>
<td>Gemcitabine (Gemzar®)</td>
<td>Pancreatic</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td></td>
<td>5FU, Oxaliplatin (FOLFOX)</td>
<td>Colon</td>
<td>Sanofi, Sun, Teva</td>
</tr>
<tr>
<td></td>
<td>Docetaxel (Taxotere®)</td>
<td>Prostate</td>
<td>Sanofi</td>
</tr>
<tr>
<td><strong>Immunotherapy</strong></td>
<td>Antibody</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab (Keytruda®)</td>
<td>Melanoma, NSCLC, Head and Neck</td>
<td>Merck and Co.</td>
</tr>
</tbody>
</table>

**NOTES:**
- NT219 will be developed in combination with approved oncology drugs to increase efficacy, expand target population, and extend treatment duration.

**TABLE:**
- **Source:** KITOV
- **Date:** 23
Summary

<table>
<thead>
<tr>
<th>Proven management team</th>
<th>Management team with track record in drug development and regulatory expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balanced and diverse pipeline</td>
<td>• Lead drug candidate Consensi™ approved for marketing in the US by FDA on May 31, 2018</td>
</tr>
<tr>
<td></td>
<td>• NT219 IND expected in 2019</td>
</tr>
<tr>
<td>Large market potential</td>
<td>• Consensi™ addresses large target population</td>
</tr>
<tr>
<td></td>
<td>• NT219 has blockbuster potential in multiple malignancies</td>
</tr>
<tr>
<td>Strong IP portfolio</td>
<td>• Consensi™ is US patent protected through 2030</td>
</tr>
<tr>
<td></td>
<td>• NT219 composition patent was granted, combination patents are pending</td>
</tr>
</tbody>
</table>